Aladdin Healthcare Technologies SE

  • WKN: A12ULL
  • ISIN: DE000A12ULL2
  • Land: Deutschland

Nachricht vom 20.07.2020 | 08:00

Aladdin Healthcare Technologies develops fully automated deep learning process to detect and distinguish COVID-19 from other diseases from CT images /research study published on IEEE Access

DGAP-News: Aladdin Healthcare Technologies SE / Key word(s): Miscellaneous
20.07.2020 / 08:00
The issuer is solely responsible for the content of this announcement.

 

Aladdin Healthcare Technologies develops fully automated deep learning process to detect and distinguish COVID-19 from other diseases from CT images /research study published on IEEE Access

- Monitored deep learning process prevents false diagnoses

- Detection and classification of Covid-19 infections from CT images

- Requirements for manual marking of CT images minimized

- Broad application of the developed technology in large-scale clinical studies possible

- Study published in the journal of the Institute of Electrical and Electronics Engineers (IEEE)

BERLIN/LONDON, July 20, 2020 - Aladdin Healthcare Technologies SE ("Aladdin", ISIN: DE000A12ULL2), a leading developer of Artificial Intelligence (AI) based healthcare diagnostics and drug discovery applications, has successfully developed a fully automated deep learning process for the detection of COVID-19-infected regions in only four months, since March 2020. The technology can prevent false diagnoses of laboratory tests and, for example, distinguish pneumonia from COVID-19 cases.

The corresponding work by Aladdin Healthcare Technologies SE has been published in IEEE Access, a journal of the Institute of Electrical and Electronics Engineers: https://ieeexplore.ieee.org/document/9127422

COVID-19 disease can be fatal because the alveoli are severely damaged and progressive respiratory failure can occur. The risk of fatality in China is 4.03%. The highest rates so far have been found in Algeria (13.04%) and Italy (12.67%).
Laboratory tests, e.g. using reverse transcription polymerase chain reaction (RT-PCR), have so far been the gold standard for clinical diagnosis, but may produce false negative results. Under the pandemic situation, a lack of testing resources may delay diagnosis and treatment. Under such circumstances, chest CT imaging has become a valuable tool for both diagnosis and prognosis of COVID-19 patients. The method minimizes the requirements for manual labeling of CT images and at the same time allows accurate infection detection. It distinguishes COVID-19 from non-COVID-19 cases.

Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies SE, comments: "Based on the promising results obtained qualitatively and quantitatively, we can envisage a wide deployment of our developed technique in large-scale clinical studies. This demonstrates the advanced capabilities of Aladdin to deliver best in class A.I. solutions even in emergency situations. The solution will be delivered to the Innovative Medicines Initiative (IMI) as part of the DRAGON project to combat COVID-19".

About Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE (and its wholly owned subsidiary Aladdin Healthcare Technologies Ltd.) is a leading developer of AI healthcare diagnostics and drug discovery applications that can accelerate both early stage disease diagnosis and the end-to-end drug discovery process. Aladdin targets age-related diseases including a significant focus on Alzheimer's disease. Aladdin accomplishes this by collaborating with numerous partners within the global healthcare ecosystem to confidentially and securely gather targeted data including, genome, tabular, MRI, PET, cognition and other lifestyle data. These datasets are then analysed by our award-winning AI team and used to develop proprietary AI tools that can assist healthcare professionals to more accurately and efficiently diagnose age-related diseases. This new diagnostic process will save significant time and costs for healthcare professionals. Additionally, our AI drug discovery platform will be used by pharmaceutical Companies to speed up drug development, clinical trials and predict outcomes more accurately.

Website Link: www.aladdinid.com
GSIN: A12ULL
ISIN: DE000A12ULL2
TICKER SYMBOL: NMI

For further information:

Aladdin Healthcare Technologies Ltd.
24-26 Baltic Street West
London EC1Y 0UR
Phone +44 7714 719696
Email: info@aladdinid.com

Contact Press
CROSS ALLIANCE communication GmbH
Sara Pinto
Phone +49 89 1250 90330
Email: pi@crossalliance.de
www.crossalliance.de



20.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Event im Fokus

14.-15.10.2020 Fachkonferenzen Finanzdienstleistungen und Technologie

11.-12.11.2020 Fachkonferenzen Software/IT und Branchenmix

Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen könnten die Fachkonferenzen im Herbst/Winter ggf. auch virtuell stattfinden.

GBC-Fokusbox

Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet

Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.

News im Fokus

Munich Re erzielt Quartalsergebnis von ca. 200 Mio. €

20. Oktober 2020, 15:37

Aktuelle Research-Studie

CytoTools AG

Original-Research: CytoTools AG (von BankM AG): Kaufen

19. Oktober 2020